1. , , , et al. 2009. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet 41:240–5.
2. , , , et al. 2005. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102:10604–9.
3. , , , et al. 2001. Epigenetic instability in ES cells and cloned mice. Science 293:95–7.
4. . 2002. DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21.
5. . 2007. Perceptions of epigenetics. Nature 447:396–8.
6. , . 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 Suppl:245–54.
7. . 2007. Chromatin modifications and their function. Cell 128:693–705.
8. , . 2007. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8:93–103.
9. , . 2007. Nuclear organization of the genome and the potential for gene regulation. Nature 447:413–7.
10. , , . 2007. Noncoding RNAs and gene silencing. Cell 128:763–76.
11. , , . 2007. The mammalian epigenome. Cell 128:669–81.
12. , , , et al. 2009. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5:e1000602.
13. , . 2007. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253–62.
14. , , , et al. 2004. Epigenetic programming by maternal behavior. Nat Neurosci 7:847–54.
15. , , , . 2007. Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J 13:9–16.
16. . 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–98.
17. . 2008. Epigenetics in cancer. N Engl J Med 358:1148–59.
18. , . 2007. The epigenomics of cancer. Cell 128:683–92.
19. . 2005. Cancer epigenetics. Hum Mol Genet 14 Spec No 1:R65–76.
20. . 2005. DNA methylation and human disease. Nat Rev Genet 6:597–610.
21. . 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21:5400–13.
22. , . 2004. The history of cancer epigenetics. Nat Rev Cancer 4:143–53.
23. . 2002. Cancer epigenomics. Hum Mol Genet 11:2479–88.
24. , . 2002. DNA methylation: a profile of methods and applications. Biotechniques 33:632, 634, 636–49.
25. . 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–66.
26. . 2005. Novel methods for analysis of genomic DNA methylation. Anal Bioanal Chem 381:67–8.
27. , , . 2007. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251:187–98.
28. , . 2007. Methods of DNA methylation analysis. Curr Opin Clin Nutr Metab Care 10:576–81.
29. , , , et al. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827–31.
30. , , , , . 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–6.
31. , , , . 2002. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res 30:e28.
32. , , , et al. 1993. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res 21:5604–8.
33. . 1998. DNA chips: state-of-the art. Nat Biotechnol 16:40–4.
34. , , , et al. 2006. Classification of DNA methylation patterns in tumor cell genomes using a CpG island microarray. Cytogenet Genome Res 114:16–23.
35. , , , et al. 2005. Microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet 37:645–51.
36. , , , et al. 2006. Genome-wide high-resolution mapping and functional analysis of DNA methylation in Arabidopsis. Cell 126:1189–201.
37. , , , et al. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37:853–62.
38. , , , et al. 2006. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res 34:e82.
39. , , , et al. 2006. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 66:6118–28.
40. , , . 1999. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8:459–70.
41. , , , et al. 2006. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 16:1046–55.
42. , , , et al. 2002. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 30:e21.
43. , , , et al. 2006. Human embryonic stem cells have a unique epigenetic signature. Genome Res 16:1075–83.
44. , , , et al. 2006. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16:383–93.
45. , , , et al. 2009. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113:2488–97.
46. . 2007. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther 9:231–41.
47. , , , et al. 2006. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3:e486.
48. , , , et al. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400.
49. , , , et al. 2005. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–6.
50. , , , . 2004. The use of chromatin immunoprecipitation assays in genome-wide analyses of histone modifications. Methods Enzymol 376:349–60.
51. , , , . 2006. Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 40:365–9.
52. , , . 2006. Highly parallel genomic assays. Nat Rev Genet 7:632–44.
53. , , , et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–80.
54. , , , et al. 2005. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309:1728–32.
55. , , , et al. 2009. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19:438–51.
56. , , , et al. 2008. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133:523–36.
57. , , , et al. 2008. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452:215–9.
58. , , , et al. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129:823–37.
59. , , , et al. 2008. Genome-wide relationship between histone H3 lysine 4 mono- and tri-methylation and transcription factor binding. Genome Res 18:1906–17.
60. , , , et al. 2008. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40:897–903.
61. , , , , . 2002. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 21:4183–95.
62. , , , et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552–6.
63. , , , et al. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404:1003–7.
64. , , , et al. 2003. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 12:2209–19.
65. , , , . 2007. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 67:11481–6.
66. , . 2005. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol 83:374–84.
67. , , , et al. 2003. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31:1765–74.
68. , , , et al. 2003. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22:6335–45.
69. , , , et al. 2005. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19:667–78.
70. , , , , , . 2006. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 66:8342–6.
71. , , , et al. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187–91.
72. , , , et al. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386–9.
73. , , , , . 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 20:2536–44.
74. , , , et al. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338–42.
75. , , , . 2003. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31:2305–12.
76. , , , et al. 2003. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035–40.
77. , , , et al. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871–4.
78. . 2005. Transposons reanimated in mice. Cell 122:322–5.
79. , , , et al. 2007. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3:2023–36.
80. , . 2001. Translating the histone code. Science 293:1074–80.
81. , , , et al. 2006. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38:1378–85.
82. , , . 2000. Large-scale methylation analysis of human genomic DNA reveals tissue-specific differences between the methylation profiles of genes and pseudogenes. Hum Mol Genet 9:2651–63.
83. , , , et al. 2002. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res 12:543–54.
84. , , , et al. 2007. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457–66.
85. , , , et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766–70.
86. , . 2001. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2:21–32.
87. , , , et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–26.
88. , , , et al. 2006. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8:532–8.
89. , . 2006. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–56.
90. . 2006. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94:179–83.
91. , . 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89–92.
92. , , , . 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455.
93. , , , et al. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300:489–92.
94. , . 2005. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 65:8635–9.
95. . 2003. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 109:17–28.
96. , , , , . 2008. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27:404–8.
97. . 1999. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 59:1743s–6s.
98. . 2002. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2:577–84.
99. , , , et al. 2009. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4:255–64.
100. , , , et al. 2009. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 4:e6986.
101. , , , et al. 2003. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114–21.
102. . 2007. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1:R50–R9.
103. , , , et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132–8.
104. , , , et al. 2001. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001–7.
105. , , , et al. 2000. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16–17.
106. , , , et al. 2006. Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 45:656–67.
107. , , , et al. 2007. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. Int J Cancer 121:547–54.
108. , , , et al. 2001. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61:8375–80.
109. , , , et al. 2007. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 17:1529–36.
110. , , , et al. 2007. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 120:701–11.
111. , , , et al. 2007. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5:153–63.
112. , , , et al. 2002. Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods 27:162–9.
113. , , , et al. 2007. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177:1753–8.
114. , , , et al. 2005. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7:748–60.
115. , , , et al. 2005. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 26:471–9.
116. , , , et al. 2006. Microarray analysis of promoter methylation in lung cancers. J Hum Genet 51:368–74.
117. , , , . 2006. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 66:7939–47.
118. , , , et al. 2007. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 104:5527–32.
119. , , , et al. 2006. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 27:2409–23.
120. , , , et al. 2007. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res 35:e51.
121. , , , et al. 2007. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 99:1270–3.
122. , , , et al. 2008. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
123. , , , et al. 2005. Differential DNA methylation of gene promoters in small B-cell lymphomas. Am J Clin Pathol 124:430–9.
124. , , , et al. 2006. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 20:1855–62.
125. , , , et al. 2005. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann Hematol 84:236–44.
126. , , , et al. 2007. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 28:60–70.
127. , , , et al. 2007. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 67:2617–25.
128. , , , et al. 2005. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23:3886–96.
129. , , , et al. 2008. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 3:e1882.
130. , , , et al. 2008. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22:1529–38.
131. , , , et al. 2009. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–25.
132. , , , et al. 2008. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366–73.
133. , , , et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178–86.
134. , . 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–31.
135. . 2005. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15:563–8.
136. , . 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–66.
137. , , , et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834–8.
138. , , , et al. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–9.
139. , , , et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635–47.
140. , , , et al. 2006. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20:2202–7.
141. , , , et al. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435–43.
142. , , , et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67:1424–9.
143. , , , et al. 2009. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69:4443–53.
144. , , , et al. 2009. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 27:1316–22.
145. , , , et al. 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556–61.
146. , , , et al. 2006. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 38:149–53.
147. , . 2007. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle 6:1040–3.
148. , , , , . 2003. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA 100:12253–8.
149. , , , et al. 2006. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38:540–9.
150. , , , et al. 2008. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 105:4844–9.
151. , , , et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237–42.
152. , , , et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39:232–6.
153. , , , et al. 2007. Epigenetic stem cell signature in cancer. Nat Genet 39:157–8.
154. , , . 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33.
155. , , , et al. 2009. Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation. Epigenetics 4:107–13.
156. , , . 2009. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res 69:282–91.
157. , , , et al. 2004. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110:362–7.
158. , , , et al. 2003. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 10:333–8.
159. , , , et al. 2005. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8:86–94.
160. , , , et al. 2003. Misregulation of histone acetylation in Sertoli cell-only syndrome and testicular cancer. Mol Hum Reprod 9:757–63.
161. , , , et al. 2004. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther 311:968–81.
162. , , , , . 2005. Antioxidants and trichostatin A synergistically protect against in vitro cytotoxicity of Ni2+ in human hepatoma cells. Toxicol In Vitro 19:173–82.
163. , , , , . 2004. Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev Biol 276:337–51.
164. , , , , . 2002. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem 277:39195–201.
165. , , . 2006. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 5:65–70.
166. , , , . 2007. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World J Gastroenterol 13:2209–13.
167. , , , , , . 2004. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol 10:2643–6.
168. , , , . 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–19.
169. , , , et al. 2006. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2:e40.
170. , , , et al. 2008. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741–50.
171. , . 2007. Genome–epigenome interactions in cancer. Hum Mol Genet 16 Spec No 1:R96–R105.
172. , . 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–28.
173. , , , et al. 1995. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195–9.
174. , , , et al. 2007. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci USA 104:20001–6.
175. , . 2007. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25:2498–510.
176. , , , . 1993. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8:3161–4.
177. , , , et al. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678–90.
178. , . 2005. A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65:11241–6.
179. . 2006. The necessity of a human epigenome project. Carcinogenesis 27:1121–5.
180. . 2005. It is time for a Human Epigenome Project. Cancer Res 65:11229.
181. , , , . 2006. German human methylome project started. Cancer Res 66:7378.
182. . 2006. Momentum building for human epigenome project. J Natl Cancer Inst 98:84–6.
183. , , , . 2004. Future potential of the Human Epigenome Project. Expert Rev Mol Diagn 4:609–18.
184. . 2003. Human epigenome project – up and running. PLoS Biol 1:e82.
185. , , , et al. 2004. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol 2:e405.
186. , , , et al. 2009. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 27:361–8.
187. , , , et al. 2009. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 27:353–60.
188. , , , et al. 2009. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res 19:1593–605.
189. , , , et al. 2009. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol 4:265–70.